论文部分内容阅读
目的探讨康泉改进方案预防原发性肝癌化疗栓塞术后恶心、呕吐的临床应用价值。方法将６０例肝癌患者随机分为两组。治疗组３０例，采用康泉改进方案，即康泉３ｍｇ加地塞米松１０ｍｇ和安定１０ｍｇ，化疗栓塞当天控制急性恶心呕吐；甲氧氯普胺３０ｍｇ加地塞米松１０ｍｇ，术后第３、５天控制迟发性反应。对照组３０例，采用康泉３ｍｇ、化疗栓塞当天注射。结果治疗组急性呕吐和恶性控制率分别为１００％和９３．３％，明显优于对照组的７３．３％和６６．７％（Ｐ＜０．０１），而且控制迟发性呕吐的疗效也优于对照组。结论康泉改进方案可提高预防原发性肝癌化疗栓塞术后恶心呕吐的疗效。
Objective To explore the clinical application value of Kangquan improvement plan in preventing nausea and vomiting after primary hepatocellular carcinoma chemoembolization. Methods 60 patients with liver cancer were randomly divided into two groups. In the treatment group, 30 patients were treated with Kangquan regimen, namely Kangquan 3mg plus dexamethasone 10mg and diazepam 10mg. The day of chemoembolization controlled acute nausea and vomiting; Metoclopramide 30mg plus dexamethasone 10mg. Controlled on postoperative day 3 and 5 Delayed response. In the control group, 30 patients were treated with Kangquan 3mg and chemoembolization on the same day. Results The rates of acute vomiting and malignant control in the treatment group were 100% and 93.3%, respectively, which were significantly better than those in the control group (73.3% and 66.7%, P<0.01), and the efficacy of controlling vomiting was delayed. Also better than the control group. Conclusion Kangquan improved regimen can improve the efficacy of preventing nausea and vomiting after chemoembolization of primary liver cancer.